Nuvectis Pharma, Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference

First of all, thank you very much. Thank you for inviting us to the conference. It's a pleasure to be here. My name is Ron Bentsur. I'm the CEO and also co-founder of Nuvectis. Prior to Nuvectis, the management team was involved with three different companies, Keryx Biopharmaceuticals, Stemline Therapeutics, and UroGen Pharma. I was the CEO of both Keryx and UroGen, and a longstanding board member at Stemline. At each one of these companies, we were fortunate enough to get a drug approved. At Keryx, it was a drug called Auryxia, which actually has two approvals. The first one as a hyperphosphatemia agent for dialysis patients, and the one that actually was very important to the transaction that we did with Haisco was as an anemia agent for pre-dialysis patients.

That is important because one of the assets that we brought in as part of the transaction, obviously, is anemia-related. At UroGen and Stemline, we got oncology drugs approved. I am sure some of you follow UroGen, and some of you recall Stemline, which was acquired by Menarini in 2020. That is the background, and we started Nuvectis in late 2021. We completed the transaction with Haisco about 2 months ago, 2 and a half months ago. Courtesy of Cantor, we did a follow-on offering right after that. We raised $150 million, and here we are.

The transaction with Haisco came together as a result of—it is basically a 2-year relationship that started out with the oncology compound that we brought in also as part of the transaction. In fact, when it was still late pre-clinical. One of our people at Nuvectis took an interest in the compound and started the dialogue with Haisco about that compound, which we now call NXP200. It obviously went into clinical trials and showed some very good data and responses, and we became very interested from a business development perspective. That kind of went along, and during that process, they also introduced us to the second compound, which we call NXP100, which is the complement Factor B inhibitor. About a year ago or so, maybe a little bit more, we were introduced to that compound. We started dialogue around both of them.

It took time, and obviously the chemistry between the teams needed to be there, and they needed to feel confident enough in our ability to move this down the field. Again, we were fortunate enough to be able to bring in these 2 compounds. We are very happy with the transaction, and they are a terrific, in fact, an incredible partner, extremely smart, and truly an exceptional development team over there.

Sure. We conducted obviously very extensive due diligence on all the aspects that you would expect. Pre-clinical, CMC, IP, of course, and of course, all the clinical data. I think it's also important to add that we closed our deal in June of this year, so about 2 months ago. Right before us, in fact, in the second quarter of 2026, Haisco closed 2 big pharma deals. The first one was with AbbVie, and about a month or a month and a half later, they closed a deal with Eli Lilly. As you can imagine, they went through the wringer in terms of due diligence, and they passed with flying colors. I think we're in a great position. We feel very comfortable with Haisco as a partner.

Yeah. FABHALTA is really the first and only Factor B on the market. It's an oral, and it's kind of slowly but surely overtaking the PNH space for 2 reasons. One, it's an oral versus SOLIRIS and ULTOMIRIS, which are injectables. But also the data for the Factor B is superior, and it's not even close actually. If you compare the data for the Factor B versus SOLIRIS and the C5s, there were 2 studies that were conducted. One was by Novartis with FABHALTA doing a head-to-head study against SOLIRIS. The second one was Eisai with our drug NXP100 doing a head-to-head study against SOLIRIS, and it's not even close. The Factor B are clearly superior to the C5s.

When you combine those two factors together, the fact that you are talking about an oral, which is much easier, and a much better drug, I do not think it is a question of if, it is really a question of just how fast the Factor B are going to overtake this multi-billion dollar market. The PNH market currently is about $5 billion, maybe $5.5 billion, soon to become $7 billion or $8 billion. That is the expectation by the end of the decade. A multi-billion dollar market that is going to be overtaken by the Factor B, initially FABHALTA, of course, and then hopefully us. You talk about the differentiation. We are once a day, they are twice a day. Obviously, there is a huge convenience advantage there. Think about lifelong therapies. These are all lifelong therapies, and we are not talking about keeping patients compliant for the first week.

Obviously, everyone is going to be compliant for a week or several months. The question is what happens after years and years of treatment. You do not want to lose compliance, especially not in a disease like PNH, because that can lead to very adverse outcomes. Keep in mind that before any drugs were introduced into the PNH market, the life expectancy of patients from diagnosis was less than 15 years because unfortunately, many of them died due to thrombotic events. The fact that SOLIRIS and ULTOMIRIS made it onto the scene was a huge blessing for the patients. Now they live pretty much a normal lifespan, but they have to be controlled. If they start losing compliance, they can run into these events, and these events can become deadly. You have to make sure compliance is airtight.

The fact that we can show up there with a once a day versus a twice a day, again, talking about years and years of treatment, we think can be a pretty substantial advantage.